ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ALDX Aldeyra Therapeutics Inc

3.34
0.26 (8.44%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 859,171
Bid Price 3.30
Ask Price 3.35
News (1)
Day High 3.4991

Low
1.42

52 Week Range

High
11.97

Day Low 3.12
Company Name Stock Ticker Symbol Market Type
Aldeyra Therapeutics Inc ALDX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.26 8.44% 3.34 19:17:55
Open Price Low Price High Price Close Price Prev Close
3.12 3.12 3.4991 3.27 3.08
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,638 859,171 $ 3.35 $ 2,874,065 - 1.42 - 11.97
Last Trade Time Type Quantity Stock Price Currency
19:44:18 6 $ 3.30 USD

Aldeyra Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
192.59M 58.90M - 0 -62.03M -1.05 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aldeyra Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALDX Message Board. Create One! See More Posts on ALDX Message Board See More Message Board Posts

Historical ALDX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.983.49912.852.94272,8200.3612.08%
1 Month3.794.342.713.35515,480-0.45-11.87%
3 Months3.384.342.713.32481,811-0.04-1.18%
6 Months6.126.741.422.741,788,176-2.78-45.42%
1 Year8.9811.971.424.911,388,247-5.64-62.81%
3 Years11.1315.951.426.851,089,746-7.79-69.99%
5 Years9.3415.951.426.94882,780-6.00-64.24%

Aldeyra Therapeutics Description

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Your Recent History

Delayed Upgrade Clock